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Cross-linking of FcγRIII (CD16) by immune complexes induces antibody-dependent 
cellular cytotoxicity (ADCC) by natural killer (NK) cells, contributing to control of intra-
cellular pathogens; this pathway can also be targeted for immunotherapy of cancerous 
or otherwise diseased cells. However, downregulation of CD16 expression on activated 
NK cells may limit or regulate this response. Here, we report sustained downregulation 
of CD16 expression on NK cells in vivo after intramuscular (but not intranasal) influenza 
vaccination. CD16 downregulation persisted for at least 12 weeks after vaccination and 
was associated with robust enhancement of influenza-specific plasma antibodies after 
intramuscular (but not intranasal) vaccination. This effect could be emulated in vitro by 
co-culture of NK cells with influenza antigen and immune serum and, consistent with 
the sustained effects after vaccination, only very limited recovery of CD16 expression 
was observed during long-term in vitro culture of immune complex-treated cells. CD16 
downregulation was most marked among normally CD16high CD57+ NK cells, irrespec-
tive of NKG2C expression, and was strongly positively associated with degranulation 
(surface CD107a expression). CD16 downregulation was partially reversed by inhibition 
of ADAM17 matrix metalloprotease, leading to a sustained increase in both CD107a 
and CD25 (IL-2Rα) expression. Both the degranulation and CD25 responses of CD57+ 
NK cells were uniquely dependent on trivalent influenza vaccine-specific IgG. These 
data support a role for CD16 in early activation of NK cells after vaccination and for 
CD16 downregulation as a means to modulate NK cell responses and maintain immune 
homeostasis of both antibody and T cell-dependent pathways.
Keywords: nK cells, cD16, cD57, degranulation, cD25, vaccination, influenza
inTrODUcTiOn
Natural killer (NK) cell effector function can be augmented by vaccination as a result of antibody-
dependent cellular cytotoxicity (ADCC) and CD4+ T cell/IL-2-driven cytokine secretion (1–4). 
Moreover, we have recently observed that vaccination induces intrinsic changes in NK cell function, 
resulting in enhanced responsiveness to innate cytokines that may synergize with adaptive immunity 
to further potentiate NK cell responses (3).
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; AEU, arbitrary ELISA units; HCC, high concentration of 
cytokines; NK, natural killer; TIV, trivalent influenza vaccine.
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Natural killer cell-mediated ADCC plays an important role 
in the control of infections and cancers (5, 6). NK cells express a 
number of immunoglobulin Fc receptors, with high expression 
of the activating receptor FcγRIIIA (CD16) and low expression 
of FCγRII (CD32) being a key feature of CD56dim NK cell popula-
tions (7, 8). Cross-linking of CD16 by IgG bound to target cell 
surface antigens leads to degranulation and release of perforin 
and granzymes. One particular subset of NK cells, character-
ized by low expression of CD56 but high levels of expression of 
CD16, CD57, and CD94/NKG2C, has recently been reported to 
be particularly efficient at mediating ADCC and may indeed be 
highly specialized for this particular effector function (9, 10). 
Furthermore, adaptive expansions of NK cells from HCMV-
infected individuals have high frequencies of FcεRγ1−, PLZF− 
NK cells with potent ADCC activity against virus-infected target 
cells (11, 12).
Regulation of NK cell ADCC is achieved in part by the relative 
strength of signals transduced through activating Fc receptors 
and NK cell inhibitory receptors but may also rely on matrix-
metalloproteinase-9 (MMP9) or ADAM17-mediated cleavage of 
CD16 from the cell surface after cross-linking by IgG (13–15). 
For example, rituximab-mediated targeting of CD20+ tumor cells 
results in potent downregulation of NK cell CD16 that is depend-
ent on MMP9-mediated cleavage (13, 14); exposure of NK cells to 
HCMV-infected fibroblasts leads to loss of CD16 concurrent with 
increased degranulation (9); MMP-dependent downregulation of 
CD16 is a feature of chronic HIV-1 infection (16, 17); and soluble 
NK cell-derived CD16 is elevated during rheumatoid arthritis, 
a chronic immune complex-associated inflammatory disease 
(18). However, similar effects have also been reported among 
cytokine-activated NK cells (stimulated in vitro with IL-2, IL-12, 
and IL-18) (19–21), suggesting that cross-linking of CD16 may 
not be essential for its downregulation. Importantly, neither the 
kinetics of CD16 expression after cross-linking nor the functional 
consequences of CD16 downregulation have been explored in 
any depth.
Here, we have investigated CD16 expression by NK cells from 
healthy subjects and find that CD16 is downregulated for many 
weeks after influenza vaccination, that CD56dim CD57+ NK cells 
are particularly prone to losing CD16 after vaccination, and 
that this is mediated by vaccine antigen–antibody complexes. 
Furthermore, we show that ADAM-17 inhibitors or blocking 
antibodies to ADAM-17 prevent shedding of CD16 in response 
to vaccine antigens and that sustained CD16 signaling potentiates 
NK cell degranulation and CD25 expression. These data support 
a role for CD16 downregulation in regulating NK cell responses 
in vivo and maintaining homeostasis of both antibody and T cell-
dependent pathways of NK cell activation.
MaTerials anD MeThODs
subject recruitment and sample 
collection
Venous blood was taken from a total of 47 healthy volunteers. The 
precise number of study subjects for each experiment is stated in 
the respective figure legends. The impact of recent vaccination 
on NK cells was studied in 37 healthy adult volunteers (median 
age 37.5 years; range of 21–63 years). None of the subjects had 
been previously vaccinated against influenza and none had 
experienced influenza-like symptoms during the previous 
6  months. Subjects were randomly assigned to receive a single 
dose of 2012–2013 seasonal trivalent influenza vaccine (TIV) by 
either the intramuscular (Split Virion BP, Sanofi Pasteur MSD) or 
intranasal (Fluenz, AstraZeneca, UK) route. Randomization was 
structured so that participants in the two arms of the study could 
be matched according to age and sex. The intramuscular vaccine 
contains chemically inactivated virus, while the intranasal vaccine 
contains live attenuated virus. The vaccines were preservative free 
and were not adjuvanted. Venous blood samples were obtained 
immediately prior to vaccination and then at 2, 4, 12, and up to 
36 weeks after vaccination. The study was approved by the ethical 
review committee of the London School of Hygiene and Tropical 
Medicine (Ref 6237). Locally recruited volunteers participating 
in influenza vaccination studies were provided with a participant 
information sheet detailing the studies. All participating vol-
unteers provided written consent. The study made use of fully 
licensed vaccines which are routinely used in clinical practice. 
The study Clinician (Dr. Behrens) provided medical supervision 
for all procedures during the baseline visit and was available for 
emergencies during subsequent visits and was on hand to provide 
follow-up care for volunteers who experience side effects of the 
procedures.
Plasma was stored for assay of antibodies to influenza and for 
use in autologous cell cultures. PBMC were separated by standard 
Histopaque (Sigma, UK) gradient centrifugation and stimulated 
within 3  h of blood collection (for immediate culture experi-
ments) or cryopreserved at 1 × 107 cells/ml in RPMI 1640, 40% 
fetal calf serum (FCS), 10% DMSO (Sigma, UK), within 4 h of 
blood collection. Cells were stored for 18 h at –80°C in Nalgene™ 
cryoboxes with isopropanol coolant prior to transfer to liquid 
nitrogen for longer term storage (22, 23).
cell culture conditions, nK cell activation
For each individual, cells collected at baseline and at each post-
vaccination time point were tested side-by-side. Cryopreserved 
PBMC were thawed, washed, and counted in Fastread™ counting 
slides (Immune Systems, UK), as previously described (22, 23), 
with a median yield of 56% and viability by trypan blue exclusion 
of 98%. Cells were rested for 4–6 h, in the absence of exogenous 
cytokines, prior to stimulation. Briefly, 2  ×  105 PBMC were 
cultured for a total of 6 h, or where indicated for 18 h, in culture 
medium alone or with inactivated TIV (Split Virion BP, Sanofi 
Pasteur MSD). Cells were also stimulated with high concentra-
tions of cytokines (HCC): IL-12 (5  ng/ml) plus IL-18 (50  ng/
ml). For in vitro assays, FITC-conjugated anti-CD107a antibody 
(clone HP9, Beckton Dickinson) was added at the beginning of 
the culture, according to established protocols (24). GolgiStop 
(containing Monensin; 1/1500 concentration; BD Biosciences, 
Oxford, UK) and GolgiPlug (containing Brefeldin A; 1/1000 
final concentration; BD Biosciences, Oxford, UK) were added 
3  h before the end of the incubation. Assays were performed 
in 1% pooled AB serum, batch tested for performance in NK 
cell assays (Sigma, UK) unless otherwise stated. To determine 
3Goodier et al. Vaccine-Mediated Downregulation of CD16
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the role of IgG on NK cell responses, pooled AB plasma was 
depleted of IgG using a protein G sepharose column (Millipore, 
UK), as previously described (23). In vitro neutralization experi-
ments were performed using a rat-anti human IL-2 antibody 
(Rat IgG2a, clone MQ1-17H12, NA/LE, BD Biosciences) or a 
rat IgG2a control reagent (eBioscience, UK).
ADAM 17/MMP-dependent cleavage of CD16 was tested 
using the inhibitor TAPI-1 at a concentration of 10 μM (Merck 
Millipore, UK) and the active site-specific anti-ADAM17 
monoclonal antibody D1 (A12) at a concentration of 6  μg/
ml (Millipore, UK) and responses compared with the DMSO 
vehicle (Sigma, UK) and isotype-matched mouse IgG1 control 
(eBioscience, UK) treatments. Optimal concentrations of inhibi-
tors were based on published protocols (25, 26) and confirmed 
by titration. Inhibitors were added 30 min prior to stimuli unless 
otherwise stated.
Long-term, in vitro culture of NK cells was performed after 
stimulation of PBMC for 18  h and washing cells (three times) 
to remove stimuli. Cells were maintained in RPMI 1640 sup-
plemented with 5% AB serum and 0.75 ng/ml of IL-15, replacing 
the medium every 3  days. CD16 expression was monitored by 
flow cytometric analysis up to 18 days after initial stimulation, as 
described below.
Flow cytometric and imagestream™ 
analysis
Phenotypic and functional analysis of NK cells was performed 
with the following monoclonal antibodies: anti-CD3-V500 
(Clone UCHT1), anti-CD56-PeCy7 (B159), anti-CD107a-FITC 
(H4A3) (all from BD Biosciences), anti-CD57-e450 (TB01), 
anti-CD16-APC (CB16), and anti-CD69 PE (all from eBiosci-
ence). Dead/apoptotic cells were excluded using APC-efluor780-
conjugated fixable viability dye (eBioscience). Cells were acquired 
on an LSRII flow cytometer (BD Biosciences, Oxford, UK) using 
FACSDiva® software.
Data analysis was performed using FlowJo V10 (Tree Star). 
FACS gates set on unstimulated cells (medium alone or isotype 
controls) were applied across all samples and all conditions. 
Responses where the gated subset contained <100 events were 
excluded. CD57+ subsets were gated using an isotype-matched 
control reagent (mIgG1-eFluor450, eBioscience). Sample gating 
strategies are shown in Figure 1.
Image-stream™ analysis was performed to test for inter-
nalization of CD16 after activation. 2  ×  106 freshly isolated 
PBMC were cultured for a total of 5  h in the presence of 
antigen and human plasma. FCS was substituted as a nega-
tive control for human Ig-containing plasma. After 5  h, cells 
were labeled with the following monoclonal antibodies for 
detection of surface antigens: anti-CD3 PE, anti-CD56PeCy7, 
anti-CD16APC (Clone 3G8, Biolegend), and anti-CD57e450 
and were blocked for an additional 15 min with unconjugated 
anti-CD16 (Clone 3G8, BD Biosciences) antibody to ensure 
occupation of all relevant epitopes prior to intracellular stain-
ing. After fixation and permeabilzation [Fix-Perm kit (BD 
Biosciences)], cells were incubated for a further 30  min with 
anti-CD16 Pe-Dazzle 594 (Clone 3G8, Biolegend) to detect 
any internalized CD16. PBMC were then washed in permwash 
buffer (BD Biosciences) and resuspended in PBS at a minimum 
concentration of 2  ×  107/ml. Events were acquired on an 
ImageStream® X Mark II Imaging Flow Cytometer (Amnis®) 
using the associated INSPIRE® software for acquisition and 
IDEAS® software for analysis. FACS gates were set based on 
FCS controls and applied across all samples and conditions. 
CD56+ CD3− NK cells were inspected visually to determine 
the presence or absence of internalized CD16.
statistical analysis
Statistical analysis was performed using GraphPad Prism ver-
sion 6.02. Linear trends were evaluated using repeated measures 
ANOVA. Functional responses between different culture condi-
tions or between vaccination time points were compared using 
Wilcoxon signed-rank test. Significance levels are assigned as 
*p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 for all tests.
resUlTs
cD16 is Downregulated on nK cells after 
intramuscular influenza Vaccination and 
is antibody Dependent
Intramuscular vaccination with inactivated, trivalent seasonal 
influenza vaccine (TIV) significantly enhanced plasma concen-
trations of influenza-specific IgG up to 36 weeks after vaccina-
tion (Figure  1A) whereas little or no change in systemic IgG 
concentrations was seen after intranasal vaccination with the live 
attenuated influenza vaccine (LAIV) (Figure 1B).
To see whether vaccination affected the phenotype of periph-
eral blood NK cells, PBMC collected before vaccination and 2, 
4, and 12  weeks after vaccination were stained immediately ex 
vivo for surface expression of CD56, CD16 and, as a marker of 
NK cell maturity, CD57. Examples of the flow cytometric gating 
strategy are shown in Figures  1C–F. Among those vaccinated 
intramuscularly with TIV, CD16 expression (MFI) on CD56dim 
NK cells was significantly reduced 2 weeks after vaccination in 
comparison to the pre-vaccination (baseline level) (Figure 1G); 
this was sustained for at least 12 weeks post-vaccination and was 
most pronounced among the CD57+ subset. In complete contrast, 
there was no significant change in CD16 expression on NK cells 
of those vaccinated intra-nasally with LAIV (Figure 1H).
As downregulation of CD16 correlated with induction of anti-
influenza antibodies, we hypothesized that these two observations 
were causally linked. To determine whether anti-influenza IgG 
contributed to CD16 downregulation, we cultured PBMC (col-
lected at baseline, 0 weeks) with or without TIV antigens in the 
presence of autologous plasma collected at baseline (0 weeks) or 
after vaccination (2 weeks) (Figures 1I,J). Significant downregula-
tion of CD16 was observed in cells cultured with autologous week 
0 plasma and TIV antigen compared to without antigen, presum-
ably reflecting the presence of pre-existing, influenza-specific 
antibodies resulting from prior infection (Figures 1I,J). However, 
when cells were cultured with TIV and 2 weeks post-vaccination 
plasma from TIV-vaccinated donors, there was a pronounced 
further reduction in CD16 expression on both CD57− and CD57+ 
NK cells compared to cells cultured without antigen (Figure 1I) 
FigUre 1 | Downregulation of nK cell cD16 expression after vaccination.  
(Continued)
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FigUre 2 | immune complex-induced shedding and sustained 
downregulation of nK cell cD16 expression. (a) Downregulation of 
CD16 requires IgG-replete human plasma and TIV antigen. PBMC were 
cultured for 5 h in FCS, IgG-depleted human plasma or IgG-replete plasma in 
the presence or absence of TIV. (B) ImageStream™ analysis of NK cells after 
5 h culture with TIV plus human plasma (containing anti-influenza IgG) or 
FCS. Examples are shown of CD56dim CD57+ NK cells stained for surface 
(external) and intracellular (internal) CD16. (c) Time course for recovery of 
CD16 expression in vitro. Expression of CD16 was tracked by flow cytometry 
up to 18 days after culture of PBMC from five separate donors with TIV for 
18 h in the presence of 1% human plasma (containing anti-influenza IgG). 
CD16 expression is shown for CD56bright, CD56dimCD57−, and CD56dim CD57+ 
NK cell subsets. Trend analysis was performed using a one-way repeated 
measures ANOVA (*p < 0.05).
(a,B) Increased plasma concentrations of anti-influenza IgG after (a) intramuscular (I.M, n = 17) but not after (B) intranasal vaccination (I. N, n = 18) up to 36 weeks 
after vaccination. Data represent median values with interquartile ranges. (c–F) Flow cytometric gating to assess the impact of vaccination on CD16 expression in 
CD56dim, CD57−, or CD57+ NK cell subsets, ex vivo. NK cells were gated as CD56+ CD3− (c) and then as CD56bright, CD56dimCD57− or CD56dimCD57+ (D). (e,F) For 
determination of antigen-driven effects CD16+ CD56+ NK cells were gated among PBMC cultured with TIV and immune plasma (e) or immune plasma without TIV 
(F). Ex vivo analysis of CD16 expression at baseline (0), 2, 4, and 12 weeks after intramuscular (I. M) vaccination with TIV (g) or intranasal (I.N.) vaccination with LAIV 
(h). Impact on NK cell CD16 expression of culturing baseline PBMC with TIV (shaded bars) or without TIV (open bars) and either pre- (0) and post- (2) vaccination 
I.M. (i) or I.N. (J) plasma; data are shown for CD56dim, CD57−, and CD57+ NK subsets after 6 h of in vitro culture with TIV. Trend analysis was performed using a 
one-way repeated measures ANOVA. Paired comparisons between pre- and post-vaccination plasma were made using Mann–Whitney U test. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001.
FigUre 1 | continued
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but no such effect was observed with post-vaccination plasma 
from LAIV-vaccinated donors (Figure  1J). Furthermore, for 
TIV-vaccinated donors, the extent of CD16 downregulation was 
dependent on plasma concentration, and was seen in both CD57− 
and CD57+ NK cells and in both NKG2C+ and NKG2C− NK cell 
subsets (Figures S1A,B Supplementary Material). Together, these 
data indicate that downregulation of CD16 is a sensitive indicator 
of vaccine-induced IgG concentration.
Downregulation of cD16 on nK cells 
is Due to cD16 shedding and is slow 
to recover
IgG-dependent downregulation of CD16 may be due to inter-
nalization of CD16–IgG–Ag complexes or to cleavage of CD16 
at the cell surface and shedding into the extracellular milieu. 
Downregulation of CD16 did not occur in cells cultured in FCS 
or in either IgG-depleted or IgG-replete human plasma in the 
absence of TIV antigen. CD16 downregulation was seen only 
when cells were cultured in IgG-replete plasma with TIV antigen 
but not when TIV antigen was added to cultures containing FCS 
or IgG-depleted plasma (Figure  2A). To determine whether 
CD16 was internalized after IgG–Ag cross-linking, NK cells were 
incubated with TIV plus IgG-replete (immune) human plasma 
or FCS for 5 h and analyzed by Imagestream™ for extracellular 
and intracellular CD16 (Figure 2B). Surface staining for CD16 
was clearly visible on CD56dim CD57+ NK cells cultured with 
TIV +  FCS but not on cells cultured with TIV and immune 
human plasma. In neither case was CD16 detected intracellularly, 
indicating that loss of CD16 from the cell surface was not accom-
panied by internalization of intact CD16.
The sustained downregulation of CD16 observed ex vivo after 
TIV vaccination suggested that recovery of CD16 expression 
may be a slow process. To test this, downregulation of CD16 was 
induced by culturing PBMC with TIV and autologous plasma for 
18 h; after washing to remove unbound antigen and antibody, the 
cells were maintained in a low concentration of IL-15 for 18 days 
(Figure 2C). CD16 expression was totally ablated on CD56dim NK 
cells 24 h after activation and remained low until day 7 when there 
was a partial but sustained recovery; a further slight increase in 
CD16 expression was seen among CD57+ NK cells between 15 
and 18 days. However, CD16 expression remained significantly 
below baseline levels in both CD57+ and CD57− NK cells until at 
least 18 days after activation. These data, taken together with our 
ex vivo observations, suggest that CD16 downregulation persists 
for several weeks after exposure to antigen in the presence of 
specific antibody.
FigUre 3 | Downregulation of cD16 correlates with degranulation.  
(Continued)
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(a,B) Flow cytometry gating strategy for CD107a expression on CD56+ NK cells cultured with immune plasma (a) with or (B) without TIV. (c,D) Proportions of 
CD56dim, CD56dimCD57− and CD56dim CD57+ NK cells expressing CD107a after culture of baseline PBMC for 6 h with TIV (shaded bars) or without TIV (open bars) in 
the presence of baseline (0) or 2 weeks post-vaccination (2) plasma. Individuals (n = 10 per group) were vaccinated I.M. with TIV (C) or I.N. with LAIV (D). (e,F) 
Correlation between CD16 expression (MFI) and frequency of CD107a-expressing NK cells within CD57− (e) and CD57+ (F) NK cells after culture for 6 h with TIV 
and immune plasma. Comparisons between conditions were made using Mann–Whitney U test. Correlations were performed using linear regression. *p < 0.05, 
**p < 0.01, ***p < 0.001.
FigUre 3 | continued
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Downregulation of cD16 correlates with 
Degranulation
As CD16 downregulation is IgG–Ag-mediated and, thus, likely 
linked to ADCC, we explored the relationship between influ-
enza vaccination, NK cell CD16 expression and degranulation 
(Figure  3). PBMCs were collected at baseline from TIV- and 
LAIV-vaccinated donors and cultured for 6  h with or without 
TIV and autologous plasma collected at baseline or 2 weeks after 
vaccination. Sample plots for analysis of CD107a expression 
are shown for NK cells cultured in autologous plasma with TIV 
or, as a negative control, without TIV (Figures 3A,B). Modest, 
but statistically significant, degranulation was seen in cells 
cultured with baseline (week 0) plasma for both TIV-vaccinated 
(Figure 3C) and LAIV-vaccinated (Figure 3D) individuals, again 
likely reflecting the presence of anti-influenza antibodies due to 
environmental exposure. Degranulation was, however, further 
enhanced in the presence of post-vaccination plasma (2 weeks) 
from TIV-vaccinated individuals (Figure 3C) but not from indi-
viduals receiving LAIV (Figure 3D). As expected, degranulation 
responses were stronger among CD57+ NK cells than among 
CD57− NK cells and CD16 expression was strongly inversely 
associated with CD107a expression (Figures 3E,F). As expected, 
for TIV-vaccinated donors, the extent of CD107a expression was 
dependent upon plasma concentration, and was greater among 
CD57+ NK cells than among CD57− NK cells, although there was 
no evidence that NKG2C+ cells responded more strongly than 
NKG2C− cells (Supplementary Figure S1 C,D).
shedding of cD16 is Mediated by aDaM17
CD16 shedding was significantly reduced on both CD57− and 
CD57+ NK cells when they were incubated with TIV and 
immune plasma in the presence of the ADAM17 inhibitor, 
TAPI-1 (Figure  4A) but not when incubated with the DMSO 
vehicle control. Notably, TAPI-1-mediated maintenance of CD16 
expression was associated with enhanced degranulation as indi-
cated by a significant increase in the frequency of CD107a+ cells, 
particularly within the highly cytotoxic CD56dimCD57+ subset 
(Figure 4B). While there is a modest trend toward an increase in 
CD16 MFI when NK cells are cultured with FCS in the presence 
of TAPI-1, this is not statistically significant and there is no effect 
on degranulation. Moreover, blocking the active site of ADAM17 
with a specific monoclonal antibody also prevented IgG–TIV-
mediated shedding of CD16 (Figure 4C) and enhanced CD107a 
expression, although to a somewhat lesser extent than the TAPI-1 
inhibitor (Figure  4D); these effects were not observed when 
cells were cultured in FCS rather than immune human serum. 
However, although specific monoclonal antibody blockade of 
ADAM17 was sufficient to prevent CD16 shedding, the more 
effective enhancement of degranulation by the TAPI-1 inhibi-
tor suggests that this may additionally target other molecules 
involved in the discharge or recycling of cytotoxic granules.
early immune complex-Mediated 
responses condition later events
Our previous studies have suggested that early, antibody-
dependent mechanisms may synergize with antigen-specific 
T  cell responses to enhance NK cell responses to vaccines (3, 
23). Since sustained expression of CD16 in the presence of 
ADAM17/MMP inhibitors led to enhanced degranulation 
(Figure 5), we investigated whether prevention of CD16 shed-
ding would affect other NK cell responses. ADAM17/MMP 
blockade had no impact on IgG–TIV-induced CD69 expres-
sion, nor was there any impact on CD25 expression after 6  h 
of culture (Figure S2 in Supplementary Material). However in 
18 h cultures, addition of TAPI-1 (Figures 5A–C) or blocking 
antibody to ADAM17 (Figures 5D–F) 30 min before the start 
of the culture (time – 0.5 h) not only sustained CD16 expression 
(Figures 5A,D) and enhanced CD107a expression (Figure 5B) 
but also significantly enhanced CD25 expression compared to 
control cultures (Figures  5C,F). However, when addition of 
TAPI-1 or anti-ADAM17 was delayed for 6  h after the initia-
tion of cultures (+ 6 h) CD16 expression could not be rescued 
(Figures 5A,D) and there was no enhancement of degranulation 
or CD25 expression (Figures 5B,C,E,F).
Bi-directional cross-talk between  
cD16-Mediated and cytokine-Mediated 
Pathways of nK cell activation
The data presented in Figure  5 are consistent with a role for 
 antigen–antibody complex signaling via CD16 in induction of 
CD25 as well as in degranulation/cytotoxicity. To explore this 
 further, PBMCs were cultured with TIV for 18 h in the presence of 
intact immune plasma or immune plasma that had been depleted 
of IgG by passage over a protein G column (Figure 6). The con-
centration of anti-TIV–IgG in intact plasma was 413.4 arbitrary 
ELISA units (AEU)/ml and this was reduced to 7.4 AEU/ml after 
protein G depletion.
As expected, there was complete loss of CD16 from the surface 
of NK cells cultured for 18  h with TIV and immune plasma. 
CD16 shedding was seen in both CD57− and CD57+ NK cells 
and was completely prevented by depleting the immune plasma 
of IgG (Figure  6A). Also as expected from our previous data, 
degranulation was inversely correlated with CD16 expression: 
CD107a expression was induced by TIV plus immune plasma 
FigUre 4 | shedding of cD16 is mediated by aDaM17. PBMCs were cultured for 6 h with TIV and FCS or immune AB plasma (AB) in the presence or absence 
of the MMP inhibitor TAP1-1 (a,B) or the D1(A12) blocking antibody to ADAM17 (c,D) and the relevant negative controls (DMSO and mIgG1, respectively). CD16 
(MFI) (a,c) and CD107a (%) (B,D) were assessed by flow cytometry on CD56dim, CD56dimCD57− and CD56dimCD57+ NK cells. Data are presented for 10 different 
individuals. Paired comparisons between conditions were made using Mann–Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.
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in both CD57+ and CD57− subsets (Figure  6B). However, this 
effect was reversed by culture with IgG-depleted only for CD57+ 
NK cells, consistent with this subset being more dependent on 
direct activation by TIV–IgG complexes (Figure  6B). In line 
with observations in Figure  5, TIV plus immune plasma also 
significantly upregulated CD25 expression on all NK cell subsets 
(Figure  6C). CD25 upregulation was dependent upon IgG–Ag 
immune complexes, particularly within CD57+ NK cells, since 
no induction of CD25 was observed when cells were cultured 
with TIV and IgG-depleted plasma (Figure 6C).
These observations suggest that there is cross-talk between 
the CD16 immune complex-mediated pathway and the cytokine-
mediated pathway of NK cell activation. To determine whether 
this cross-talk was bi-directional, CD16, CD107a, and CD25 
expression were characterized on PBMCs incubated for 18  h 
with recombinant IL-12 and IL-18. As shown previously (3, 23, 
27), IL-12+IL-18 induces degranulation and strongly upregu-
lates CD25 expression on both CD57− and CD57+ NK  cells 
(Figures 6E,F). Importantly, however, IL-12+IL-18 also induced 
significant shedding of CD16 from the surface of NK  cells 
(Figure  6D), indicating that cytokine-mediated activation of 
NK cells may restrict their subsequent antibody-dependent 
responses. Also, as high concentrations of IL-2 have previously 
been reported to downregulate CD16 (19), and as IL-2 might 
be being produced in these cultures by TIV-specific T cells, we 
added neutralizing anti-IL-2 antibodies to our cultures to test 
whether IL-2 might be contributing to CD16 downregulation. 
However, neutralization of IL-2 did not affect downregulation of 
CD16 by TIV/IgG nor the associated induction of CD107a and 
CD25 (Figures 6A–C).
FigUre 5 | early immune complex-mediated responses condition later events. PBMCs were cultured for a total of 18 h with TIV and FCS or immune AB 
plasma (AB) in the presence or absence of the MMP inhibitor TAP1-1 (a–c) or the D1(A12) blocking antibody to ADAM17 (D–F) and the relevant negative controls 
(DMSO and mIgG1, respectively). CD16 (MFI) (a,D), CD107a (%) (B,e), and CD25 (c,F) expression were assessed by flow cytometry. TAPI-1, DMSO, D1(A12), 
or mIgG1 were added either 30 min prior to (−0.5), or 6 h after (+6) TIV antigen. Data are presented for eight different individuals. Paired comparisons between 
conditions were made using the Mann–Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.
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DiscUssiOn
It is increasingly being recognized that human NK cells are 
functionally as well as phenotypically heterogeneous, with mark-
ers of NK cell differentiation and maturation correlating with 
effector function. More differentiated NK cells, bearing high 
levels of CD57 and also expressing CD16, NKG2C, KIR, and the 
FcεRγ adaptor protein, appear specialized for ADCC, whereas 
CD57− NK cells (both CD56bright and CD56dim subsets) are highly 
sensitive to exogenous cytokines. However, NK cell function 
is not binary: CD57− NK cells express CD16 and can mediate 
ADCC whereas CD57+ NK cells can be induced to secrete IFN-γ 
under certain circumstances. Moreover, as shown here, immune 
complex-mediated pathways of NK cell activation influence 
cytokine-induced pathways, and vice versa.
Natural killer cells are essential for resistance to infection and 
cancer but – if unregulated – have the potential to cause significant 
immunopathology (28); NK cell activation is well known, there-
fore, to be very tightly controlled by the balance of activating and 
inhibitory signals. However, rather less attention has been paid to 
regulating the consequences of NK cell activation and restoring 
immune homeostasis after an infection or other threat has been 
controlled or eliminated. It is in this context that downregulation 
of CD16 after cross-linking by immune complexes is likely to be 
of functional significance.
Internalization, degradation, or shedding of cell surface recep-
tors after ligation by their cognate ligand is a characteristic of the 
immune system and appears designed to release active soluble 
mediators or to ensure that immune responses are self-limiting 
(29). Here, we have demonstrated that downregulation of CD16 
FigUre 6 | Bi-directional cross-talk between cD16-mediated and cytokine-mediated pathways of nK cell activation. (a–c) PBMCs were cultured for 
18 h with or without TIV in the presence of immune plasma (IgG+) or IgG-depleted immune plasma (IgG−) or after treatment with anti-IL-2 neutralizing antibody or 
isotype-matched control and expression of CD16 MFI (a), CD107a (%) (B), or CD25 (%) (c) on CD56dim, CD56dimCD57−, and CD56dimCD57+ NK cells was assessed 
by flow cytometry. (D–F) PBMCs were cultured for 18 h with or without IL-12 (5 ng/ml) combined with IL-18 (50 ng/ml) and expression of CD16 MFI (D), CD107a 
(%) (e), or CD25 (%) (F) on CD56dim, CD56dimCD57−, and CD56dimCD57+ NK cells was assessed by flow cytometry. Paired comparisons were made using the  
Mann–Whitney U test. *p < 0.05, **p < 0.01, ***p < 0.001.
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on NK cells after cross-linking by IgG–Ag immune complexes is 
an example of such self-regulation, curtailing NK cell degranula-
tion and limiting their ability to respond to exogenous cytokines 
by constraining expression of the high-affinity IL-2 receptor. 
Moreover, we have shown that CD16 downregulation is due to 
ADAM17-mediated shedding of CD16 from the NK cell surface, 
is induced in  vivo after systemic vaccination, and is sustained 
for at least 12 weeks in vivo and at least 18 days in vitro. Taken 
together, these data suggest that tightly controlled surface expres-
sion of CD16 represents an important mechanism for regulating 
NK cell function in vivo.
It has previously been shown that broad spectrum matrix 
metalloprotease inhibitors allow recovery of CD16 expression in 
cytokine-maintained NK cells from HIV-1 infected individuals 
(16) and prevent downregulation of CD16 in vitro in response 
to cytokines or PMA (19, 20). We have confirmed these obser-
vations, revealing a very specific role for the ADAM17 class of 
proteases in this process, and extended them to show that inhibi-
tion of CD16 shedding can potentiate NK cell cytotoxic function, 
opening up potential therapeutic applications. However, TAPI-1 
treatment enhanced degranulation more consistently than 
blockade with the ADAM-17-specific monoclonal antibody, 
suggesting that although reported as an ADAM-17 specific, 
this inhibitor may target additional MMPs involved in cytolytic 
granule processing (30, 31).
The prolonged period of CD16 downregulation in  vivo/ 
ex vivo after immunization (at least 3 months) was a surprise and 
raises questions about the ability of NK cells to mediate ADCC 
reactions in the immediate aftermath of vaccination or infection. 
Given that this is a global, generic effect rather than an antigen-
specific effect, the consequences could be wide-ranging and 
might conceivably contribute to the increased risk of secondary 
infection after a primary viral infection, for example. Indeed, 
cross-linking of CD16 with rituximab (anti-CD20) has been 
shown to induce SHP-1-dependent hypo-responsiveness of NK 
cells to a diverse array of activating signals, including third-party 
tumor cell lines and cross-linking of NKp46, 2B4, NKG2D, and 
DNAM-1 (32). CD16 cross-linking and downregulation may, 
therefore, represent a dominant early pathway for controlling 
NK cell activation, affecting diverse NK cell signaling pathways. 
In line with this, we observed that CD16 downregulation also 
affects cytokine-mediated pathways of NK cell activation, and 
vice versa, raising further questions about the consequences of 
this homeostatic mechanism. It suggests, for example, that CD4+ 
T cell/IL-2-mediated activation of NK cells (3, 23, 27) may be 
unable to fully compensate for the inhibition of the ADDC 
pathway. On the other hand, CD25 expression by CD57− NK 
cells – which are the major cytokine-producing subset of NK cells 
(27, 33) – was less affected by loss of CD16 (by comparison with 
CD57+ cells), indicating that cytokine responsiveness may be 
retained by a subset of the NK cell population despite widespread 
downregulation of CD16.
Persistence of CD16low NK cells has been reported in chroni-
cally HIV-1 infected individuals despite effective suppression of 
viral replication by anti-retroviral therapy (16), but persistence 
of antigen – and, thus, of immune complexes – cannot be ruled 
out in this case. While long-term persistence of antigen cannot 
be entirely ruled out in our TIV model, the vaccine is inactivated. 
On the other hand, our data do imply that individual NK cells 
may have very limited capacity to re-express CD16 once it has 
been lost: NK cells that had been induced to shed CD16 showed 
very little propensity to re-express CD16 over a period of more 
than 2 weeks in culture, despite the absence of IgG or antigen. 
Recovery of the CD16+ NK cell population in vivo may, thus, rely 
on repopulation of the periphery from NK cell precursors.
Finally, our study raises questions about the nature of protection 
induced by influenza vaccination. The very low levels of circulat-
ing IgG induced by the live attenuated intra-nasal vaccine, and the 
correspondingly low levels of NK cell degranulation/ADCC/CD16 
shedding, suggest that NK cell ADCC to influenza is not potenti-
ated by LAIV. Anti-influenza IgG antibodies not only mediate NK 
cell ADCC but are sufficient to control virulent (H1N1 pandemic) 
infection in rhesus macaques in the absence of neutralizing anti-
bodies (34, 35). It is interesting to speculate, therefore, that the lack 
of this ADCC response may in part explain the apparently much 
lower efficacy of LAIV compared to TIV that is now being rec-
ognized (CDC Advisory Committee on Immunization Practices, 
http://www.cdc.gov/media/releases/2016/s0622-laiv-flu.html).
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